Whether it's a new dieting fad or a modern spin on a common workout routine, people will try just about anything to live a healthier, fitter life. At the center of diabetes and obesity medications sit pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly. These two companies are the developers behind popular treatments Ozempic, Rybelsus, Wegovy, Saxenda, Jardiance, and Mounjaro. I'd put it at better-than-even odds that you've seen a commercial for at least one of these medications.

The demand for these appetite-curbing supplements is off the charts. And while both Novo Nordisk and Eli Lilly have witnessed generous financial returns from the popularity of these treatments, there is more to the story.

Both companies are battling supply challenges due to the unprecedented demand. Let's take a look at what that means and assess if these growth stocks deserve a position in your portfolio. 

Continue reading

Source Fool.com